Johnson & Johnson Seeks Emergency Use Authorization For Its COVID-19 Vaccine

Pharmaceutical company Johnson & Johnson’s single-shot COIVD-19 vaccine has been shown to be 66% effective in preventing moderate to severe cases of the virus in a global clinical trial. In those with very severe symptoms, the vaccine is 85% effective. The company is now seeking an Emergency Use Authorization in the United States. While already-approved vaccines from Pfizer/BioNTech and Moderna are more than 95% effective, Dr. Anthony Fauci said that vaccines like Johnson & Johnson’s can help mediate supply bottlenecks occurring in the U.S. “If we can alleviate that, that is really important –…

Read More

HEDGE accordingly